Company news
Aeolus Pharmaceuticals Inc (OTC:AOLS) news
Aeolus Pharmaceuticals Inc news releases on 6ix. Latest, Mar 23, 2018: Aeolus Announces Commencement of Assignment for the Benefit of Creditors
Press releases & updates
Aeolus Announces Commencement of Assignment for the Benefit of Creditors
March 22, 2018
Aeolus Announces Presentation of Pharmacometric Analysis Confirming Statistically Significant Improvement in Survival 6 Months After Exposure to Lethal Thoracic Radiation Following Treatment with AEOL 10150
September 25, 2017
Aeolus Announces Presentation of Pharmacometric Analysis of Data Establishing Optimal Dose Schedule of AEOL 10150 for Treatment of Lung Radiation Damage
September 21, 2017
Aeolus Announces Publication of Data Demonstrating that Adding AEOL 10150 to Standard Therapy After Nerve Agent Exposure Improves Survival and Reduces Brain Damage and Nerve Inflammation in Rats
September 19, 2017
AEOLUS' AEOL 10150 is Safe and Well Tolerated in Phase 1 Study in Healthy Subjects
September 17, 2017
Aeolus Announces Third Quarter Financial Results for Fiscal Year 2017
August 13, 2017
Aeolus Announces FDA Fast Track Designation Granted to AEOL 10150 for Treatment of Patients With Lung Acute Radiation Syndrome Following a Radiologial or Nuclear Event
June 8, 2017
Aeolus Announces Second Quarter Financial Results for Fiscal Year 2017
May 15, 2017
Aeolus Receives BARDA Decision Regarding Additional Options for Lung ARS Development Contract; Files Response to Assertions Made by BARDA in the Notification
March 23, 2017
AEOL 20415 Protects Lungs Against Infection in Animal Model of Cystic Fibrosis
March 15, 2017
Aeolus Initiates Phase 1 Study of AEOL 10150 in Healthy Normal Volunteers
February 22, 2017
Aeolus Announces Fiscal Year 2016 Financial Results
December 21, 2016
Aeolus Announces Publication of Additional Data Demonstrating Efficacy of AEOL 10150 in Sulfur Mustard Exposure in Journal "Toxicological Sciences"
September 19, 2016
Aeolus Announces Positive Data Confirming Efficacy of AEOL 10150 as a Medical Countermeasure Against Sulfur Mustard Gas
September 6, 2016
Aeolus Pharmaceuticals to Present at Aegis Growth Conference on September 22, 2016
August 31, 2016
Aeolus Announces Third Quarter Fiscal Year 2016 Financial Results
August 15, 2016
StockNewsNow.com Publishes New SNNLive Video Interview with Aeolus Pharmaceuticals, Inc. Discussing Clinical Development and Milestones for 2016-2017
July 7, 2016
Aeolus Pharmaceuticals to Present at LD Micro Invitational Conference
May 24, 2016
European Patent Issued and Patent Allowed in Japan for Aeolus' Parkinson's Disease Compound AEOL 11114
April 18, 2016
Aeolus Announces Removal of FDA Clinical Hold on AEOL 10150; Initiation of Phase 1 Study in Healthy Volunteers Planned for 2nd Quarter 2016
February 22, 2016
Aeolus Announces First Quarter Fiscal Year 2016 Financial Results
February 16, 2016
Aeolus Announces Fiscal Year 2015 Financial Results
December 18, 2015
Aeolus Announces $6.75 Million Private Placement Financing
December 15, 2015
Aeolus Announces Formation of Pulmonary Fibrosis Clinical Advisory Board
November 4, 2015
Aeolus Receives Notice of Patent Allowance for New Compound That Demonstrated Efficacy in Michael J. Fox Foundation Research Grant Program
November 2, 2015
Aeolus Announces Publication of Study Showing AEOL 10150 Improves Memory and Protects Brain Damage in an Animal Model of Epilepsy
August 18, 2015
Aeolus Announces Third Quarter Fiscal Year 2015 Financial Results
August 17, 2015
Barda Exercises $3 MM in Additional Contract Funding for Development of AEOL 10150 as Treatment for Acute Radiation Syndrome
June 26, 2015
Aeolus Pharmateucticals to Present at LD Micro Invitational Conference
May 28, 2015
OTC Markets Group Welcomes Newly Verified OTCQB Companies – May 19
May 19, 2015
Aeolus Announces Second Quarter Fiscal Year 2015 Financial Results
May 15, 2015
Aeolus Announces Complete Results From Successful Study Showing AEOL 10150 Doubles Survival Rate Following Lung Damage Caused by Acute Radiation Exposure
May 4, 2015